Funding for this research was provided by:
U.S. Department of Veterans Affairs
Received: 31 December 2021
Accepted: 28 February 2022
First Online: 8 March 2022
: The Institutional Review Board (IRB) at the VA Northeast Ohio Healthcare System approved the study protocol. The IRB at the VA Northeast Ohio Healthcare System also granted a waiver of informed consent because the research was no more than minimal risk and the waiver would not adversely affect the participants’ rights and welfare. All research activities were performed in accordance with the relevant guidelines and regulations.
: Not applicable.
: None of the authors have relevant conflicts of interest to disclose. RJ and FP have received research funding from the Accelerate and Merck outside of the submitted work. RJ has participated in advisory boards for Pfizer and Merck.